Sanofi will fill and pack hundreds of thousands of doses of Pfizer’s COVID-19 vaccine from July in an effort to assist meet the large demand for the U.S. drugmaker’s photographs.
Pfizer and its German accomplice BioNTech are, like different COVID-19 vaccine producers similar to AstraZeneca, struggling to fulfill the large demand for photographs which are the world’s finest wager for overcoming the pandemic.
Final month, Sanofi and Britain’s GlaxoSmithKline mentioned a COVID-19 vaccine they’re collectively growing had proven an inadequate immune response in older individuals, delaying its launch to late this yr.
The corporate has been beneath strain since to hunt methods of serving to with COVID-19 vaccines devised by different drugmakers as the pandemic intensifies once more in Europe and elsewhere.
“Since our primary vaccine is a couple of months late, we requested ourselves how we might be of help now,” Hudson was quoted as saying.
Sanofi can also be engaged on one other COVID-19 vaccine candidate with U.S. agency Translate Bio which makes use of mRNA know-how, much like the method of Pfizer/BioNTech. Part I trials are anticipated to begin this quarter.
Hudson confirmed within the interview that Sanofi stays dedicated to its two vaccine tasks.